Artelo Biosciences, Inc.

ARTL

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001621221


None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $2.8M
Warnings	dilution, thin data not computable: short runway, degenerate inputs, distress, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Feb 24, 2026 259 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$2.03 2026-11-09; market equity $9.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the "ECS"), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. Our product candidate pipeline broadly leverages leading scientific methodologies and balances risk across mechanisms of action and stages of development.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 3.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(116.3%)	(6.6%)	3.6	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 92.6					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(108.87)	(0.35)	95.7	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	(58.78x)	(4.51x)	84.4	78	2025-12-31
Current ratio	0.17x	2.95x	97.8	826	2025-12-31
Growth and financing, sleeve percentile 94.8					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(48.4%)	2.2%	98.4	694	2025-12-31
Net share issuance, one year	288.6%	2.5%	91.2	629	2026-02-20

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 288.6%
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(56.6%)	(1.9%)	12
Distance from 52-week high	(80.4%)	(27.5%)	8
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.53	0.27	72
Sales to price	not computable	0.29	
Composite equity issuance, five years	440.8%	20.8%	97
Relative strength against the sector, log excess return	(1.00)	(0.19)	12

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	90 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$172,910

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$12.9M	2025-12-31	2026-02-24	10-K	26-000368
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.5M	2025-12-31	2026-02-24	10-K	26-000368
3	assets	us-gaap:Assets	$2.8M	2025-12-31	2026-02-24	10-K	26-000368
4	assets	us-gaap:Assets	$4.7M	2024-12-31	2026-02-24	10-K	26-000368
5	current assets	us-gaap:AssetsCurrent	$695,000	2025-12-31	2026-02-24	10-K	26-000368
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.0M	2025-12-31	2026-02-24	10-K	26-000368
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$63.0M	2025-12-31	2026-02-24	10-K	26-000368
8	operating income	us-gaap:OperatingIncomeLoss	-$11.4M	2025-12-31	2026-02-24	10-K	26-000368
9	book equity	us-gaap:StockholdersEquity	-$1.3M	2025-12-31	2026-02-24	10-K	26-000368
10	liabilities	us-gaap:Liabilities	$4.1M	2025-12-31	2026-02-24	10-K	26-000368
11	interest expense	us-gaap:InterestExpense	$194,000	2025-12-31	2026-02-24	10-K	26-000368
12	assets	us-gaap:Assets	$13.0M	2023-12-31	2025-03-03	10-K	25-000335
13	assets	us-gaap:Assets	$20.4M	2022-12-31	2024-03-25	10-K	24-000473
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,124,772	2026-02-20	2026-02-24	10-K	26-000368
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,281,032	2025-02-27	2025-03-03	10-K	25-000335

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.